Literature DB >> 11756975

Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein.

Rupinderjeet Kaur1, Geetanjali Sachdeva, Sudhanshu Vrati.   

Abstract

Plasmid DNA synthesizing membrane-anchored or secretory Japanese encephalitis virus (JEV) envelope (E) protein and premembrane protein was delivered to mice by intramuscular injection or gene gun. Intramuscular plasmid immunization induced anti-E antibody responses similar to those associated with commercial JEV vaccine. The gene gun induced less antibody response. The 2 forms of the E protein induced similar antibody titers when administered by the same delivery mode. Both plasmids generated high titers of JEV-neutralizing antibodies, although the titers were lower than those induced by the vaccine. Intramuscular DNA immunization induced T helper 1 (Th1) immune responses, and the gene gun induced Th2 responses. Compared with secretory E protein, the membrane-anchored protein heavily skewed the immune response toward either Th1 or Th2, depending on the route of immunization. In an intracerebral JEV challenge model, plasmid-immunized mice had approximately 60% protection; this was not affected by the form of the E protein or by immunization route.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756975     DOI: 10.1086/338015

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice.

Authors:  Kaushik Bharati; Y P S Malik; Sudhanshu Vrati
Journal:  Med Microbiol Immunol       Date:  2007-03-22       Impact factor: 3.402

2.  Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice.

Authors:  Brian Nickols; Irina Tretyakova; Alexander Tibbens; Elena Klyushnenkova; Peter Pushko
Journal:  Virology       Date:  2017-09-19       Impact factor: 3.616

3.  A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge.

Authors:  Manisha Saini; Sudhanshu Vrati
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

Review 5.  Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India.

Authors:  Vandana Saxena; Tapan N Dhole
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

Review 6.  Development of a recombinant vaccine against Japanese encephalitis.

Authors:  Rupinderjeet Kaur; Sudhanshu Vrati
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643

7.  Mutation of putative N-linked glycosylation sites in Japanese encephalitis virus premembrane and envelope proteins enhances humoral immunity in BALB/C mice after DNA vaccination.

Authors:  Yu Zhang; Puyan Chen; Ruibing Cao; Jinyan Gu
Journal:  Virol J       Date:  2011-03-25       Impact factor: 4.099

8.  Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice.

Authors:  Xingsheng Wang; Guangyan Xie; Jianming Liao; Dengke Yin; Wenyan Guan; Mingjie Pan; Jingnian Li; Yuexi Li
Journal:  Virol J       Date:  2011-05-16       Impact factor: 4.099

9.  Japanese encephalitis-a pathological and clinical perspective.

Authors:  Debapriya Ghosh; Anirban Basu
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

10.  Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response.

Authors:  Fengjuan Wang; Xiuli Feng; Qisheng Zheng; Hongyan Hou; Ruibing Cao; Bin Zhou; Qingtao Liu; Xiaodong Liu; Ran Pang; Jin Zhao; Wenlei Deng; Puyan Chen
Journal:  Virol J       Date:  2012-09-17       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.